Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Interferon Gamma for Ventilator-Associated Pneumonia in ICU Patients
NCT05843786Phase 3Recruiting
- Sponsor
- Hospices Civils de Lyon
- Start
- Jun 2023
- Primary completion
- Jul 2027
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in ventilator-associated pneumonia (VAP) comparing Interferon gamma treatment with Placebo (2 arms). Primary endpoint: Duration of mechanical ventilation at Day 28. Started Jun 2023; status: recruiting.
02
Drugs
interferon gamma-1b
03
Conditions
ventilator-associated pneumonia (VAP)
Beyond the preview
Go deeper on NCT05843786.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05843786.